Literature DB >> 30481779

Galangin Alleviates Liver Ischemia-Reperfusion Injury in a Rat Model by Mediating the PI3K/AKT Pathway.

Yang Li1, Liquan Tong1, Jingyan Zhang1, Yafeng Zhang2, Feng Zhang3.   

Abstract

BACKGROUND/AIMS: Liver ischemia-reperfusion (I/R) injury is a pathological process that often occurs during liver and trauma surgery. There are numerous causes of liver I/R injury, but the mechanism is unknown. Galangin (GA) is a flavonoid, a polyphenolic compound widely distributed in medicinal herbs that has anti-inflammatory, antioxidant, and antitumor activity. This study evaluated the protective effect of GA on hepatic I/R injury.
METHODS: An I/R model was created in male Wistar rats by clamping the hepatoportal vein, hepatic artery and hepatic duct for 30 min followed by reperfusion for 2 h. A hypoxia/restoration (H/R) model was established in buffalo rat liver (BRL) cells by hypoxia for 4 h followed by normoxic conditions for 10 h. The extent of liver injury was assayed by serum ALT/AST, hepatic histology, and MPO activity. Oxidative stress was assayed by serum superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and malondialdehyde (MDA). Expression of apoptosis-related proteins in BRL cells was assayed in western blots. Expression of AKT and p-AKT proteins in vivo and vitro were assayed in western blots.
RESULTS: GA significantly decreased ALT/AST expression, reversed changes in oxidative stress markers induced by I/R, and mediated caspase-3 activity expression of apoptosis-related proteins in vivo and in vitro. Methylthiazol tetrazolium (MTT) assay, flow cytometry, and Hoechst 33258 staining confirmed that GA inhibited apoptosis of BRL cells. GA also increased the expression of phosphorylated AKT after H/R.
CONCLUSION: GA reduced liver I/R injury both in vivo and vitro and inhibited BRL cell apoptosis. PI3K/AKT signaling have been involved. GA may protect against liver I/R and be a potential therapeutic candidate.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cell apoptosis; Galangin; Liver ischemia-reperfusion injury; PI3K/AKT

Mesh:

Substances:

Year:  2018        PMID: 30481779     DOI: 10.1159/000495553

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Hesperidin ameliorates liver ischemia/reperfusion injury via activation of the Akt pathway.

Authors:  Shilai Li; Quanlin Qin; Daqing Luo; Wenhui Pan; Yuqing Wei; Yansong Xu; Jijin Zhu; Liming Shang
Journal:  Mol Med Rep       Date:  2020-10-06       Impact factor: 2.952

2.  Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway.

Authors:  Yan Wu; Gaolin Qiu; Hainie Zhang; Leilei Zhu; Gao Cheng; Yiqiao Wang; Yuanhai Li; Weiwei Wu
Journal:  J Cell Mol Med       Date:  2021-10-19       Impact factor: 5.310

3.  Preventive effect of lemon seed flavonoids on carbon tetrachloride-induced liver injury in mice.

Authors:  Ming Yang; Fengjun Sun; Yue Zhou; Mei He; Pu Yao; Yuan Peng; Fei Luo; Fu Liu
Journal:  RSC Adv       Date:  2020-03-31       Impact factor: 4.036

4.  Galangin attenuates oxidative stress-mediated apoptosis in high glucose-induced renal tubular epithelial cells through modulating renin-angiotensin system and PI3K/AKT/mTOR pathway.

Authors:  Jie Liao; Bo Liu; Ke Chen; Sheng Hu; Zheng-Yu Liu; Yu-Xin Li; Zhi-Ming Yang; Meng Zhang; Xiong Chen
Journal:  Toxicol Res (Camb)       Date:  2021-05-17       Impact factor: 3.524

5.  Galangin Activates Nrf2 Signaling and Attenuates Oxidative Damage, Inflammation, and Apoptosis in a Rat Model of Cyclophosphamide-Induced Hepatotoxicity.

Authors:  Saleem H Aladaileh; Mohammad H Abukhalil; Sultan A M Saghir; Hamza Hanieh; Manal A Alfwuaires; Amer A Almaiman; May Bin-Jumah; Ayman M Mahmoud
Journal:  Biomolecules       Date:  2019-08-05

6.  Hypoxia-inducible factor-1alpha protects the liver against ischemia-reperfusion injury by regulating the A2B adenosine receptor.

Authors:  Xingjian Zhang; Peng Du; Kaifeng Luo; Yong Li; Zhongzhong Liu; Wei Wang; Cheng Zeng; Qifa Ye; Qi Xiao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.